Back
News Non classé
1 min read

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 21 décembre 2022

Related Posts

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

Read More

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

August 24. Treatment with its antibody directed against tumor lymphocytes offers new hope for patients with PTCL

Read More

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

June, 2024. During its participation in ASCO, XENOTHERA….

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in